Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma Virus
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Carcinoma Cervix Uterine
- Carcinoma in Situ
- Cervical Intraepithelial Neoplasia Grade 2/3
- Neoplasm Cervix
- Neoplasms
- Neoplasms by Histologic Type
- Design
- Observational Model: OtherTime Perspective: Cross-Sectional
Participation Requirements
- Age
- Between 25 years and 65 years
- Gender
- Only males
Description
Women accessing the Colposcopy Centres for a colposcopy examination and fulfilling the selection criteria will be asked, after written informed consent, to self-collect a first-void urine (with the Colli-Pee device) and a vaginal sample (with the FLOQSwab device), prior to undergoing colposcopy. Jus...
Women accessing the Colposcopy Centres for a colposcopy examination and fulfilling the selection criteria will be asked, after written informed consent, to self-collect a first-void urine (with the Colli-Pee device) and a vaginal sample (with the FLOQSwab device), prior to undergoing colposcopy. Just before colposcopic examination, a clinician will also take a cervical sample (with a Cervex-Brush using the same procedure normally adopted for cervical cytology and/or HPV testing. During colposcopy, a colposcopy-targeted biopsy may be taken if appropriate. When according to colposcopy and biopsy results, an excisional treatment of a cervical precancer lesion is needed, the histology of the excised tissue will complete the end point of the study. The colposcopy and histological findings will be used as the gold standard if biopsies are taken. In case of normal satisfactory colposcopic findings without biopsy taking, colposcopy will provide the study outcome. Three new PCR-based HPV 'in vitro diagnostic devices' (Papilloplex, HPV Oncopredict RNA, HPV Oncopredict DNA) developed as part of the SME Instrument Project 'HPV OncoPredict (GA-806551)' will be assessed.
Tracking Information
- NCT #
- NCT04312737
- Collaborators
- Genefirst LTD
- Sciensano
- Investigators
- Principal Investigator: Marc Arbyn, Dr Sciensano